Description
Name: GLP-1, GIP, and Glucagon Receptor Triple-Agonist (RT)
Sequence: H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Aib-Lys-NH₂ (with C20 fatty diacid chain conjugation via linker)
Molecular Formula: C₂₈₉H₄₅₂N₇₂O₈₈
Molecular Weight: ≈ 6951.48 g/mol
CAS Registry Number: 2381089-83-2
Triple Agonist (GLP-1 / GIP / Glucagon) – COMPREHENSIVE RESEARCH PEPTIDE FOR TRIPLE RECEPTOR AND METABOLIC SIGNALING STUDIES
Scientific Overview of Triple Agonist (GLP-1 / GIP / Glucagon)
Triple Agonist (GLP-1 / GIP / Glucagon) is a synthetic triple-agonist peptide engineered to activate the GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and GCGR (glucagon) receptors simultaneously. It is a next-generation incretin-based analog designed for enhanced receptor engagement, stability, and prolonged activity through fatty acid side-chain acylation.
In in-vitro and in-vivo experimental research, Triple Agonist (GLP-1 / GIP / Glucagon) has been evaluated for its multifaceted receptor interactions and signaling dynamics, focusing on:
• Triple Receptor Co-Activation – examination of concurrent GLP-1R, GIPR, and GCGR binding and second-messenger modulation (Coskun et al., 2023)
• Energy and Metabolic Regulation Pathways – study of combined receptor effects on glucose and lipid metabolism in preclinical models (Shao et al., 2023)
• Peptide Engineering and Acylation Design – analysis of molecular modifications enhancing half-life, receptor specificity, and signal amplitude (Willard et al., 2021)
Triple Agonist (GLP-1 / GIP / Glucagon) is utilized in advanced metabolic and endocrinological research as a tool for understanding poly-agonist mechanisms and integrated receptor signaling across metabolic networks.
*This peptide is intended solely for laboratory research use. It is not approved for human consumption or therapeutic application.
COA for this item
Reviews
There are no reviews yet.